Susquehanna International Group, LLP Caribou Biosciences, Inc. Call Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$1.62 - $5.05 $42,120 - $131,300	-26,000 Reduced 64.2%	14,500 $23,000
Q1 2024 May 07, 2024	BUY	$4.82 - $8.26 $195,210 - $334,530	40,500 New	40,500 $208,000
Q3 2023 Nov 14, 2023	BUY	$4.08 - $8.14 $179,928 - $358,974	44,100 Added 288.24%	59,400 $283,000
Q2 2023 Aug 11, 2023	BUY	$4.04 - $5.47 $12,928 - $17,504	3,200 Added 26.45%	15,300 $65,000
Q1 2023 May 16, 2023	SELL	$4.3 - $7.78 $271,760 - $491,696	-63,200 Reduced 83.93%	12,100 $64,000
Q4 2022 Feb 14, 2023	SELL	$5.57 - $11.01 $205,533 - $406,269	-36,900 Reduced 32.89%	75,300 $472,000
Q3 2022 Nov 14, 2022	BUY	$5.34 - $12.79 $274,476 - $657,406	51,400 Added 84.54%	112,200 $1.18 Million
Q2 2022 Aug 15, 2022	BUY	$5.1 - $9.74 $158,610 - $302,914	31,100 Added 104.71%	60,800 $330,000
Q4 2021 Feb 14, 2022	BUY	$14.59 - $23.26 $433,323 - $690,822	29,700 New	29,700 $448,000

145

53.7M

32.5K

89.8K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $119M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.